Who
David Hollander
Chief R&D Officer
Company insider
Files Form 4 as: Chief R&D Officer, Veradermics; Director, Kiora Pharmaceuticals; CMO & Global Therapeutics Lead, Revance Therapeutics; Chief R&D Officer, Aerie Pharmaceuticals.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $16K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 11 Nov 2019
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code A | —9,650 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,300 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,300 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code A | —9,650 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Apr 2025filed 2 Apr 2025 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 6 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code D | —95,212 | filing |
| 4 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code U | $36K9,733 at $3.65 | filing |
| 18 Nov 2024filed 19 Nov 2024 | Revance Therapeutics | SEC FORM 4 Sold | $16K3,908 at $4.17 | filing |
| 1 Jul 2024filed 3 Jul 2024 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,778 at $0.00 | filing |
| 29 Sep 2023filed 3 Oct 2023 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —0 at $0.00 | filing |
| 3 Mar 2023filed 7 Mar 2023 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 4 Feb 2022filed 8 Feb 2022 | Aerie Pharmaceuticals | SEC FORM 4 Code F | $6,535927 at $7.05 | filing |
| 1 Feb 2022filed 3 Feb 2022 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 1 Feb 2022filed 3 Feb 2022 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 11 Nov 2021filed 15 Nov 2021 | Aerie Pharmaceuticals | SEC FORM 4 Code F | $26K2,162 at $12.06 | filing |
| 4 Feb 2021filed 8 Feb 2021 | Aerie Pharmaceuticals | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 4 Feb 2021filed 8 Feb 2021 | Aerie Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 11 Nov 2020filed 12 Nov 2020 | Aerie Pharmaceuticals | SEC FORM 4 Code F | $28K2,162 at $13.05 | filing |
News
No headline names them, or the companies they trade most, lately.